Cell and Gene Regulatory
-
Early Planning For CGT Commercialization: Regulatory, Manufacturing, And Market Access
9/23/2026
Commercialization decisions in cell and gene therapy are made earlier than most manufacturers expect, with regulatory, manufacturing, and market access implications that compound over time.
-
Setting The New Standard For Aseptic Processing: Esco OxAP Isolator
9/22/2026
Advanced positive-pressure isolators with integrated nebulized decontamination protect sensitive cell processing and aseptic filling operations while ensuring strict cGMP compliance.
-
Developing A Science- And Risk-Based Bio-Decontamination Control Strategy For Pharmaceutical Isolators
9/22/2026
Modern contamination control links barrier design, bio-decontamination science, and risk-based validation to ensure reliable surface sterility.
-
Powering The Development And Manufacturing Of Advanced Therapies
9/22/2026
Move advanced therapy programs forward with integrated expertise. Learn how scalable processes and connected teams can help reduce transitions, manage risk, and support broader patient access.
-
A Systematic Review Of Complete Response Letters In Cell And Gene Therapy
9/22/2026
Common themes in FDA Complete Response Letters reveal where CGT submissions often fall short, offering practical guidance for strengthening CMC readiness, preparing for inspections, and more.
-
The Case For Synthetic DNA In Modern Therapeutic Development
9/22/2026
Faster timelines, cleaner manufacturing, and regulatory momentum are driving interest in synthetic DNA. Explore how innovators are reducing bottlenecks and accelerating development.
-
2026 Regulatory Updates And Operation TrialBlazer
9/21/2026
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by former FDA staffers Eva Temkin, partner at Arnold & Porter, and Elizabeth Trentacost, senior associate at Arnold & Porter. They reflect on 2026 regulatory developments and discuss the implications and nuances of Operation TrialBlazer.
-
Can Targeted LNP Delivery Take In-Vivo CAR-T Therapy Beyond The Liver?
9/17/2026
Achieving successful extrahepatic CAR T delivery with LNPs requires addressing the unique biological and technological barriers and designing targeting approaches that leverage innovative LNP design.
-
The Phase 2 Manufacturing Wall: The CMC Risk Hiding In Plain Sight
9/17/2026
Hidden gaps in process maturity and organizational alignment can derail development. Discover how to identify risks early and improve readiness for key milestones.
-
Vertex On Building Risk Into Manufacturing Network Strategy
9/17/2026
Supply disruptions are becoming harder to predict. Explore practical strategies for continuity planning, supplier risk management, and network design to build lasting resilience.